Success Metrics

Clinical Success Rate
94.4%

Based on 17 completed trials

Completion Rate
94%(17/18)
Active Trials
6(23%)
Results Posted
29%(5 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_3
10
38%
Ph phase_1
4
15%
Ph phase_2
9
35%

Phase Distribution

4

Early Stage

9

Mid Stage

10

Late Stage

Phase Distribution23 total trials
Phase 1Safety & dosage
4(17.4%)
Phase 2Efficacy & side effects
9(39.1%)
Phase 3Large-scale testing
10(43.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

94.4%

17 of 18 finished

Non-Completion Rate

5.6%

1 ended early

Currently Active

6

trials recruiting

Total Trials

26

all time

Status Distribution
Active(8)
Completed(17)
Terminated(1)

Detailed Status

Completed17
Recruiting4
Not yet recruiting2
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
6
Success Rate
94.4%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (17.4%)
Phase 29 (39.1%)
Phase 310 (43.5%)

Trials by Status

recruiting415%
not_yet_recruiting28%
active_not_recruiting28%
completed1765%
terminated14%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT07455812

A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause

Completed
NCT06975111Phase 2

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Recruiting
NCT06440967Phase 3

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Active Not Recruiting
NCT06049797

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Completed
NCT06917313Phase 2

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Recruiting
NCT07606664Phase 3

Fezolinetant and Vascular Health and Brain Health

Not Yet Recruiting
NCT07602530

A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice

Recruiting
NCT06617455Phase 2

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

Terminated
NCT07568236Phase 2

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Not Yet Recruiting
NCT06206421Phase 3

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

Completed
NCT06812754Phase 2

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

Completed
NCT06972875Phase 2

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

Recruiting
NCT06206408Phase 3

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause

Completed
NCT04451226Phase 3

A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause

Completed
NCT04234204Phase 3

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

Completed
NCT05419908Phase 2

Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes

Completed
NCT03192176Phase 2

A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

Completed
NCT04003142Phase 3

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

Completed
NCT04003389Phase 3

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

Completed
NCT04003155Phase 3

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

Completed

Drug Details

Intervention Type
DRUG
Total Trials
26